Galapagos selected for Stoxx Europe 600 Index
November 24 2016 - 1:35AM
Galapagos NV (Euronext & NASDAQ: GLPG) announces that
Stoxx has selected Galapagos NV for inclusion in the Stoxx Europe
600 Index, effective 19 December 2016.
"After the inclusion of Galapagos in the BEL20
Index last March and, as first biotechnology company ever, in the
AEX Index last June, we are pleased to be subsequently selected for
inclusion in the Stoxx Europe 600 Index as well. The year 2016 has
truly reflected the evolution of Galapagos from a pioneering target
discovery company to an integrated biopharmaceutical powerhouse,"
says Onno van de Stolpe, CEO and Founder.
Stoxx Ltd. is a global index provider, currently
calculating a global, comprehensive index family of over 7,500
strictly rules-based and transparent indices. Best known for the
leading European equity indices EURO Stoxx 50, Stoxx Europe 50 and
Stoxx Europe 600, Stoxx Ltd. maintains and calculates the Stoxx
Global index family which consists of total market, broad and
blue-chip indices for the regions Americas, Europe, Asia/Pacific
and sub-regions Latin America and BRIC (Brazil, Russia, India and
China) as well as global markets.[1]
About GalapagosGalapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises a pipeline of Phase
3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic
fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary
Fidelta, has approximately 480 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands,
France, and Croatia. More information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
&Corporate Communications+1 781 460 1784 |
Director
Communications +31 6 53 591 999 communications@glpg.com |
Paul van der HorstDirector IR & BusinessDevelopment+31 6 53 725
199 |
|
ir@glpg.com |
|
Forward-looking statementsThis release may
contain forward-looking statements. Such forward-looking statements
are not guarantees of future results. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any forward-looking statements in this document, unless
specifically required by law or regulation.
[1] Source: www.stoxx.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/07b312c6-b578-4d03-b8e2-2aaaa78ea2ee
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024